Key Financial Metrics Signal Operational Leverage (Image Credits: Pexels)
As GSK plc released its first-quarter results on April 29, the company showcased a promising start to the year, with total sales reaching £7.6 billion, a 5 percent increase at constant exchange rates from the prior year. This performance stemmed largely from robust demand in specialty medicines, offsetting softer areas in general medicines. Chief Executive Officer Luke Miels emphasized the momentum, stating, “GSK has made a strong start to 2026, with good performance from our key growth drivers. Alongside operational delivery, we are focused on execution and accelerating R&D.”[1][2]
Key Financial Metrics Signal Operational Leverage
Core operating profit climbed 10 percent at constant exchange rates to £2.65 billion, lifting the core operating margin to 34.7 percent, up 1.8 percentage points. Core earnings per share rose 9 percent to 46.5 pence, reflecting favorable product mix, SG&A efficiencies, and higher royalty income.[1][2] Total operating profit also advanced, reaching £2.29 billion, while cash generated from operations increased 4 percent to £1.35 billion.
Free cash flow strengthened to £815 million, supporting ongoing investments and returns to shareholders. These figures underscored GSK’s ability to deliver profitability even as research and development spending grew ahead of sales.
Specialty Medicines Propel Top-Line Expansion
The standout performer was the specialty medicines segment, which posted £3.2 billion in sales, up 14 percent at constant exchange rates. HIV products contributed £1.8 billion, a 10 percent rise driven by long-acting treatments like Dovato, up 20 percent, Cabenuva, up 31 percent, and Apretude, up 16 percent. Respiratory, immunology, and inflammation sales reached £890 million, gaining 16 percent, with Nucala advancing 28 percent following its COPD approval in Europe.[2][3]
Oncology delivered £512 million, surging 28 percent, led by Jemperli at £232 million, up 40 percent, and Ojjaara/Omjjara up 34 percent. These gains highlighted patient demand and successful launches, though Blenrep dipped slightly.
Vaccines generated £2.1 billion, up 4 percent, with Shingrix achieving a record £1.0 billion, up 20 percent, fueled by higher U.S. immunization rates nearing 45 percent. Meningitis vaccines edged down 3 percent, while Arexvy fell 18 percent amid phasing. General medicines, at £2.3 billion, declined 6 percent, with Trelegy holding steady at £646 million.[1]
- HIV long-acting injectables now represent over 70 percent of segment growth.
- Nucala captured about 45 percent U.S. COPD market share post-launch.
- Shingrix U.S. growth accelerated 40 percent, Europe 34 percent.
R&D Pipeline Gathers Pace with Key Milestones
GSK advanced its pipeline significantly, securing approvals for Exdensur in Europe and China for severe asthma, Nucala for COPD in Europe, and Blenrep in China for multiple myeloma. Regulators accepted filings for bepirovirsen, a potential functional cure for chronic hepatitis B, in the U.S., Europe, China, and Japan, with data forthcoming at the EASL congress in the second quarter.[2]
Other highlights included U.S. Breakthrough Therapy and European PRIME designations for efimosfermin in MASH liver disease, plus phase I data for the Mo-Rez ADC supporting five phase III trials in 2026 for endometrial and ovarian cancers. Acquisitions bolstered the lineup: ozureprubart for food allergies and HS235 for pulmonary hypertension. Upcoming readouts span camlipixant for chronic cough, Jemperli in rectal cancer, and three-times-yearly HIV PrEP.[3]
With 57 medicines and vaccines in clinical development, these steps position GSK to sustain innovation across respiratory, oncology, and infectious diseases.
Guidance Steady, Returns Prioritized
GSK reaffirmed its full-year 2026 outlook, projecting turnover growth of 3 to 5 percent, core operating profit growth of 7 to 9 percent, and core EPS growth of 7 to 9 percent, all at constant exchange rates. Specialty medicines should see low double-digit expansion, while vaccines hold low single-digit decline to flat, and general medicines low single-digit decline to stable.[4]
A first-quarter dividend of 17 pence was declared, with 70 pence anticipated for the year. The company executed £1.7 billion of its £2 billion share buyback program so far. Net debt stood at £15.6 billion, reflecting acquisitions like RAPT Therapeutics.
Looking ahead, GSK eyes more than £40 billion in 2031 sales through pipeline execution and operational discipline. Investors will watch how specialty momentum and R&D catalysts translate into sustained growth amid evolving market dynamics.